Diverse Biotech Inc, a United States-based biopharmaceutical company, has named Stella Vnook as its new chief executive officer, it was reported yesterday.
Vnook has more than 25 years' experience. She has most recently held senior leadership roles at Assertio Pharma, Jazz Pharmaceuticals, Catalent and Merck. She started her career in Research and Development in the Emergency Department at Temple University Hospital and later continued that work with oncology specialty interest at Temple/Fox Chase Cancer Centre as a pharmacist. Throughout her career she has developed extensive knowledge in many different therapy categories with a particular emphasis on Oncology, Pain Management and Cardiovascular Diseases.
William Fisher, Diverse Biotech's board chairman, said, 'Diverse Biotech is very excited to bring Stella on board as an experienced, knowledgeable, and innovative Senior Leader. Stella will work hand in hand with the current Diverse Biotech Board to continue to build a world class, innovative, experienced Executive Team.'
Galapagos plans to wind down cell therapy business following strategic review
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Revelation Pharma acquires Acacia Apothecary & Wellness
Viatris receives fifth consecutive recognition on Forbes' annual list of World's Best Employers
INOVIO announces inducement grant to new employee
AbbVie's Allergan Aesthetics announces Natrelle supplier agreement with Vizient
Karyopharm Therapeutics awards inducement grants to new employees
POLYTECH Health & Aesthetics announces Poland expansion
Santhera Pharmaceuticals signs Gulf region distribution agreement with Uniphar